L
Labrynth
Making healthcare more accessible and efficient for patients
About Labrynth
Labrynth, operating under Daedalus Systems Inc., is a healthcare technology firm focused on connecting patients with medical research and streamlining healthcare services. The company operates a platform that serves patients, healthcare providers, clinical sites, and research institutions. For patients, Labrynth offers an application that consolidates medical records into a single secure location on their smartphone, giving them the same view of their information as their providers. This patient-centered model allows individuals to opt-in to share their data with researchers, and a predictive matching system recommends clinical trials.
For healthcare providers, Labrynth provides a light Electronic Health Record (EHR) solution designed to be cost-effective. The platform includes features for secure messaging between staff and patients, telehealth visits with screen-sharing capabilities, and electronic prescription services. The overarching business model aims to create a network that facilitates the collection, storage, and analysis of health data. This is intended to streamline medical research, accelerate the market entry of new treatments, and improve patient access to care. By creating a large, accessible pool of patient data, Labrynth seeks to reduce costs for both patients and providers while advancing medical research. The platform is designed to be HIPAA compliant, ensuring the security of sensitive health information.
The company was previously known as Daedalus Systems. The platform aggregates medical, clinical trial, and user-generated data to guide patients in their healthcare journey. This ecosystem is built to empower patients by giving them control over their health information and facilitating their participation in the research process. By connecting patients with life-saving research, the company aims to support the development of new drugs.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2021 | $11M | $45M | Undisclosed | — |
| EARLY VC✓Equity / VC | Mar 2020 | $0 | — | Khosla Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Labrynth is 50 monthly website visits. Labrynth's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Labrynth on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Labrynth’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








